Back to 2011 Program

Introduction and Objectives: We present short term surgical and quality of life outcomes in a cohort of patients that underwent robotic assisted sacrocolpopexy (RASCP) for symptomatic pelvic organ prolapse.
Methods: A prospective analysis was performed to evaluate perioperative and quality of life outcomes following RASCP for the treatment of symptomatic POP. All patients underwent multi-disciplinary evaluation including examination with a urologist and gynecologist. Prolapse was graded by the Baden-Walker staging. Candidates underwent RASCP with/without supracervical hysterectomy and urethral sling. Patients were followed postoperatively with physical examination and questionnaires (PFDI, ISS, AUASS, AUAQOL). Data was available at 3, 6 and 12 months following surgery.
Results: From 4/2010 to 4/2011, 58 patients with POP underwent RASCP. All patients underwent concomitant mid-urethral sling, (8 miniarc, 50 PVS), 30 patients underwent concomitant robotic assisted supracervical hysterectomy. Mean patient age was 59.9 years (range 45 - 80). Mean EBL was 50cc. Mean operative time was 156 minutes. Mean operative prolapse stage was 3.2 on Baden-Walker staging (0-4). Mean length of stay was 48hrs. There were no conversions. There was one bowel injury. Mean follow up was 6 months. One patient demonstrated apical recurrence at 6 months postop. Patients demonstrated statistically significant QOL improvement following surgery based on mean scores PFDI (3.6 vs 1.9, p<0.05), ISS (2.2 vs 0.8 , p<0.05)and AUASS (3.75 vs 1.5, p<0.05) and AUAQOL ( 4.3 vs 1.2 p<0.05) .
Conclusions: RASCP is a safe and highly efficacious treatment option for women with symptomatic POP. Patients reported an improvement in their QOL.